Undiscovered Swedish Stocks To Watch In July 2024

In This Article:

As global markets experience fluctuations, Sweden's small-cap stocks are drawing attention with the Russell 2000 Index recently marking a significant gain of 6.00%. This surge highlights a growing investor interest in smaller companies amid broader economic shifts and inflationary adjustments. In this context, exploring lesser-known Swedish stocks could uncover potential opportunities for investors looking to diversify and capitalize on unique market dynamics in July 2024.

Top 10 Undiscovered Gems With Strong Fundamentals In Sweden

Name

Debt To Equity

Revenue Growth

Earnings Growth

Health Rating

Duni

29.33%

10.78%

22.98%

★★★★★★

Softronic

NA

3.42%

7.64%

★★★★★★

Bahnhof

NA

9.47%

15.07%

★★★★★★

AB Traction

NA

5.38%

5.19%

★★★★★★

Firefly

NA

15.31%

29.94%

★★★★★★

Creades

NA

-28.54%

-27.09%

★★★★★★

Rederiaktiebolaget Gotland

NA

-14.29%

18.06%

★★★★★★

AQ Group

7.30%

14.89%

22.26%

★★★★★★

Karnell Group

44.29%

22.04%

39.45%

★★★★★☆

Solid F?rs?kringsaktiebolag

NA

4.38%

29.89%

★★★★☆☆

Click here to see the full list of 55 stocks from our Swedish Undiscovered Gems With Strong Fundamentals screener.

Here we highlight a subset of our preferred stocks from the screener.

Biotage

Simply Wall St Value Rating: ★★★★★★

Overview: Biotage AB (publ) specializes in solutions and products for drug discovery and development, analytical testing, as well as water and environmental testing, with a market capitalization of SEK 15.51 billion.

Operations: The company generates revenue through the sale of its products and services, achieving a gross profit margin of 62.73% as of the latest reporting period in 2024. Operating expenses for the same period were SEK 932 million, reflecting costs associated with sales, marketing, research and development, and general administrative activities.

Biotage, a notable player in the Life Sciences sector, has shown robust financial health and growth prospects. With earnings growth of 16.2% over the past year surpassing industry averages, Biotage's strategic position is further solidified by a significant reduction in its debt-to-equity ratio from 19.2% to 4%. Additionally, trading at 39.7% below its estimated fair value suggests potential for appreciation. Recent reports indicate strong performance with second-quarter sales rising to SEK 504 million from SEK 409 million the previous year, accompanied by an increase in net income to SEK 48 million from SEK 34 million.

OM:BIOT Earnings and Revenue Growth as at Jul 2024
OM:BIOT Earnings and Revenue Growth as at Jul 2024

Biotage

Simply Wall St Value Rating: ★★★★★★